Paper26320063
Antagonists of PD-1 and PD-L1 in Cancer Treatment.
Lipson EJ and 5 others. Semin Oncol, 2015. Cited by 245 papers, by iCite.
Cite this record
ConductScience Library. Antagonists of PD-1 and PD-L1 in Cancer Treatment. Papers, record 26320063. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26320063
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| B7-H1 Antigen | Major topic |
| Neoplasms | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Biomarkers, Tumor | |
| Humans | |
| Immunosuppression Therapy | |
| Tumor Microenvironment |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA142779 | NCI NIH HHS | United States | R01CA142779 | PubMed and NIH |
| R01CA142779 | NCI NIH HHS | United States | R01CA142779 | PubMed and NIH |
Source NIH RePORTER
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24608200 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. | Ann Oncol | 2014 | https://conductscience.org/library/papers/24608200 | PubMed |
| 2 | 24590637 | Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. | J Clin Oncol | 2014 | https://conductscience.org/library/papers/24590637 | PubMed |
| 3 | 24714771 | Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24714771 | PubMed |
| 4 | 25384885 | Identification and management of toxicities from immune checkpoint-blocking drugs. | Oncology (Williston Park) | 2014 | https://conductscience.org/library/papers/25384885 | PubMed |
| 5 | 25428503 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. | Nature | 2014 | https://conductscience.org/library/papers/25428503 | PubMed |
| 6 | 25428504 | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. | Nature | 2014 | https://conductscience.org/library/papers/25428504 | PubMed |
| 7 | 24831977 | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/24831977 | PubMed |
| 8 | 24842267 | Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. | Breast Cancer Res Treat | 2014 | https://conductscience.org/library/papers/24842267 | PubMed |
| 9 | 24658839 | Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. | Cancer Immunol Immunother | 2014 | https://conductscience.org/library/papers/24658839 | PubMed |
| 10 | 25428505 | PD-1 blockade induces responses by inhibiting adaptive immune resistance. | Nature | 2014 | https://conductscience.org/library/papers/25428505 | PubMed |
| 11 | 25409260 | Genetic basis for clinical response to CTLA-4 blockade in melanoma. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25409260 | PubMed |
| 12 | 25358689 | The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. | Cancer Discov | 2015 | https://conductscience.org/library/papers/25358689 | PubMed |
| 13 | 25399552 | Nivolumab in previously untreated melanoma without BRAF mutation. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25399552 | PubMed |
| 14 | 25482239 | PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25482239 | PubMed |
| 15 | 25524312 | Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25524312 | PubMed |
| 16 | 25452452 | Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25452452 | PubMed |
| 17 | 12529460 | Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. | N Engl J Med | 2003 | https://conductscience.org/library/papers/12529460 | PubMed |
| 18 | 17159987 | Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. | Nat Med | 2007 | https://conductscience.org/library/papers/17159987 | PubMed |
| 19 | 17360651 | Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17360651 | PubMed |
| 20 | 19825956 | Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19825956 | PubMed |
Cited by171
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 245 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42854695 | Spatially tuned localization of interleukins and OX40 agonists enhances synergistic anti-tumor immunity. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42854695 | PubMed |
| 42287338 | Neuropeptide Y as a Neuro-Immune Checkpoint in Cancer. | J Neuroimmune Pharmacol | 2026 | https://conductscience.org/library/papers/42287338 | PubMed |
| 41674937 | Development and validation of a herb-related gene signature for prognosis prediction and therapeutic response assessment in breast cancer. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/41674937 | PubMed |
| 41518478 | LncRNA PVT1 drives macrophage polarization and triple-negative breast cancer progression via PPARγ-mediated transcriptional activation. | Apoptosis | 2026 | https://conductscience.org/library/papers/41518478 | PubMed |
| 41228268 | Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228268 | PubMed |
| 40847228 | Recent Advancements in Immunotherapy for the Treatment of Metastatic Breast Cancer. | Cancer Treat Res | 2025 | https://conductscience.org/library/papers/40847228 | PubMed |
| 40502964 | A comprehensive review of using nanomaterials in cancer immunotherapy: Pros and Cons of clinical usage. | 3 Biotech | 2025 | https://conductscience.org/library/papers/40502964 | PubMed |
| 40444482 | Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review). | Int J Oncol | 2025 | https://conductscience.org/library/papers/40444482 | PubMed |
| 40075663 | Immune Cell Interplay in the Fight Against GBM. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40075663 | PubMed |
| 40073258 | Immune suppression sustained allograft acceptance requires PD1 inhibition of CD8+ T cells. | J Immunol | 2025 | https://conductscience.org/library/papers/40073258 | PubMed |
| 40060757 | Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy. | Bioeng Transl Med | 2025 | https://conductscience.org/library/papers/40060757 | PubMed |
| 40040557 | Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study. | Int J Urol | 2025 | https://conductscience.org/library/papers/40040557 | PubMed |
| 39966234 | The chick embryo chorioallantoic membrane as an experimental model to study immune checkpoint inhibitors. | Intern Emerg Med | 2025 | https://conductscience.org/library/papers/39966234 | PubMed |
| 39246446 | Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy. | iScience | 2024 | https://conductscience.org/library/papers/39246446 | PubMed |
| 39109293 | The Groebke-Blackburn-Bienaymé reaction in its maturity: innovation and improvements since its 21st birthday (2019-2023). | Beilstein J Org Chem | 2024 | https://conductscience.org/library/papers/39109293 | PubMed |
| 39011666 | Deciphering the tumour microenvironment of clear cell renal cell carcinoma: Prognostic insights from programmed death genes using machine learning. | J Cell Mol Med | 2024 | https://conductscience.org/library/papers/39011666 | PubMed |
| 38625861 | Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. | PLoS One | 2024 | https://conductscience.org/library/papers/38625861 | PubMed |
| 38553754 | Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies. | Breast Cancer Res | 2024 | https://conductscience.org/library/papers/38553754 | PubMed |
| 38203846 | Programmed Cell Death Ligand 1 Immunohistochemical Expression and Cutaneous Melanoma: A Controversial Relationship. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38203846 | PubMed |
| 38201238 | Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. | Cells | 2023 | https://conductscience.org/library/papers/38201238 | PubMed |
Genes16
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26320063
GET https://conductscience.org/api/papers/v1/26320063/references?page=2